AstraZeneca posts 7% Q3 revenue growth, raises dividend and launches $2 bn restructuring plan
AstraZeneca reported third‑quarter 2026 revenue of $16.21 billion, up 7% at constant exchange rates, and core earnings per share of $2.79, a 19% increase. The company announced a restructuring programme costing up to $2 billion that is expected to generate $1.5 billion of annual pre‑tax savings, which will be reinvested in its drug pipeline. It also completed a $2 billion equity investment in Summit Therapeutics and said it will raise the 2026 dividend to $3.30 per share.
Why it matters
The higher profit and dividend increase give investors immediate upside, while the cost‑saving plan aims to fund pipeline development without diluting shareholders. The restructuring and Summit stake also signal a strategic focus on oncology and rare‑disease growth as diabetes sales fall.
Key facts
- 1Q3 revenue was $16.21 billion, a 7% increase at constant exchange rates. finance.biggo.com
- 2Core EPS was $2.79, up 19% at constant exchange rates. finance.biggo.com
- 3Core operating profit rose to $5.86 billion, a 20% increase. finance.biggo.com
- 4Global Farxiga sales fell 25% to $1.61 billion; U.S. Farxiga sales fell 71% to $127 million. finance.biggo.com
- 5AstraZeneca launched a restructuring programme with one‑time charges of up to $2 billion, targeting $1.5 billion of annual pre‑tax savings. finance.biggo.com
- 6The company completed a $2 billion equity investment in Summit Therapeutics, giving roughly 12% of the biotech’s outstanding common stock. directorstalkinterviews.com
Summary written by AlphAI AI Desk from 20 of 29 sources. Not investment advice. Figures are as stated by the linked sources.